Skip to main content
  • E-cadherin as a Predictive Marker of Brain Metastasis in Non-small Cell Lung Cancer and Its Regulation by Pioglitazone in a Preclinical Model

    Final Number:

    Seung Ho Yang MD

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: It remains unclear whether patients with non-small cell lung cancer (NSCLC) develop brain metastasis during or following the standard therapy. The authors sought to identify biological markers that predict brain metastasis, and investigate the way to modulate the expression of the marker.

    Methods: A case-control study of patients who were newly diagnosed with NSCLC and who had developed brain metastasis during follow-up was conducted between 2004 and 2009. These patients were compared with a control group of patients who had NSCLC, but no evidence of brain metastasis. Immunohistochemical analyses were performed for the expression of Ki-67, p53, Bcl-2, Bax, vascular endothelial growth factor, epidermal growth factor receptor, caspase-3, and E-cadherin. Additionally, the methylation status of the genes for O6-methylguanine-DNA-methyltransferase, tissue inhibitor of matrix metalloproteinase (TIMP)-2, TIMP-3, and death-associated protein-kinase was determined using a methylation-specific polymerase chain reaction.

    Results: A significantly increased risk of developing brain metastasis was associated with the presence of primary tumors with low E-cadherin expression in patients with NSCLC. Moreover, we investigated the effects of pioglitazone, a peroxisome proliferator-activated receptor ?-activating drug, in tumor-bearing mouse models. We found that E-cadherin expression was proportional to pioglitazone exposure time. Interestingly, pioglitazone pretreatment before cancer cell inoculation prevented loss of E-cadherin expression and decreased the expression of MMP9 and fibronectin, as compared to that in the control group.

    Conclusions: E-cadherin expression could be a predictor of brain metastasis in patients with NSCLC. Preventive treatment with pioglitazone may be useful in modulating E-cadherin expression.

    Patient Care: Taken together with our findings, blocking epithelai-to-mesenchymal transition (EMT) by PPARγ-activating agents may have impact on the metastatic capacity of NSCLC in a clinical setting.

    Learning Objectives: In this study, the candidate marker of brain metastasis was assayed in a tumor-bearing mouse model treated with PPAR?-activating agent, pioglitazone to evaluate the possibility as the preventive or therapeutic target of brain metastasis.

    References: E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. J Neurooncol. 2012 Sep;109(2):219-27.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy